AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Eli Lilly Q3 Earnings Preview: Key Factors to Watch Amid Mixed Performance
ByAinvest
Monday, Oct 27, 2025 11:29 am ET1min read
Eli Lilly and Company (LLY) is set to report Q3 2025 earnings on Oct. 30. The Zacks Consensus Estimate is pegged at $16.01 billion in sales and $6.02 per share in earnings. Earnings estimates for 2025 have declined from $23.15 per share to $22.73 per share. The company has a mixed performance, exceeding earnings expectations in two of the trailing four quarters while missing in the remaining two. Lilly has an Earnings ESP of -0.66% and a Zacks Rank #3 (Hold). The key drivers of Lilly's top-line growth are expected to be its popular GLP-1 drugs, Mounjaro and Zepbound, driven by high demand trends.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet